Third generation EGFR TKI landscape for metastatic EGFR mutant non-small cell lung cancer (NSCLC)

Expert Rev Anticancer Ther. 2019 Jun;19(6):431-435. doi: 10.1080/14737140.2019.1604228. Epub 2019 Apr 14.

Authors

Aaron C Tan¹, Yi Lin Teh¹, Gillianne G Y Lai¹, Daniel S W Tan¹

Affiliation

¹ a Division of Medical Oncology , National Cancer Centre Singapore , Singapore , Singapore.

PMID: 30950666
DOI: 10.1080/14737140.2019.1604228

No abstract available

Keywords: EGFR mutation; nizartinib; non-small cell lung cancer; osimertinib; third generation EGFR TKI.

Publication types

Editorial

MeSH terms

Antineoplastic Agents / administration & dosage
Antineoplastic Agents / pharmacology
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / pathology
Drug Development
ErbB Receptors / genetics
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Mutation
Protein Kinase Inhibitors / administration & dosage*
Protein Kinase Inhibitors / pharmacology

Substances

Antineoplastic Agents
Protein Kinase Inhibitors
EGFR protein, human
ErbB Receptors